Amgen Management
Management criteria checks 3/4
Amgen's CEO is Bob Bradway, appointed in May 2010, has a tenure of 15.58 years. total yearly compensation is $24.43M, comprised of 7.7% salary and 92.3% bonuses, including company stock and options. directly owns 0.1% of the company’s shares, worth $184.13M. The average tenure of the management team and the board of directors is 5.9 years and 9 years respectively.
Key information
Bob Bradway
Chief executive officer
US$24.4m
Total compensation
| CEO salary percentage | 7.65% |
| CEO tenure | 15.6yrs |
| CEO ownership | 0.1% |
| Management average tenure | 5.9yrs |
| Board average tenure | 9yrs |
Recent management updates
Recent updates
Amgen: Improving Balance Sheet Is Bringing The Stock Close To Being A "Buy"
Dec 10Statutory Profit Doesn't Reflect How Good Amgen's (NASDAQ:AMGN) Earnings Are
Aug 13
Is Amgen (NASDAQ:AMGN) A Risky Investment?
Aug 01Amgen Inc.'s (NASDAQ:AMGN) Earnings Haven't Escaped The Attention Of Investors
Jun 20It's Unlikely That Amgen Inc.'s (NASDAQ:AMGN) CEO Will See A Huge Pay Rise This Year
May 16Amgen: The Biotech That Knows How To Make Money
Apr 17Biosimilar Competition And TEPEZZA Approvals Will Define Future Path
Declining prices combined with biosimilar competition and loss of exclusivity threaten revenue growth and profit margins.Expanding Oncology Portfolio And International Launches Will Unlock Potential
Expansion in oncology and rare diseases, coupled with strategic pipeline innovations, promises substantial long-term revenue and earnings growth.Amgen: Excellent Buy And Hold For A Volatile Market
Mar 31Amgen Inc.'s (NASDAQ:AMGN) Intrinsic Value Is Potentially 82% Above Its Share Price
Mar 29Amgen: Riding The MariTide Of Monthly Weight Loss
Mar 10Amgen Inc. (NASDAQ:AMGN) Not Flying Under The Radar
Mar 03Amgen Stock: Why I Still Rate It A 'Buy'
Feb 26Amgen Q4 Earnings: Good Quarter, Ok Guidance, But MariTide Concerns Me (Rating Downgrade)
Feb 06Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.38
Feb 01Amgen: Likely To Be Rangebound (Rating Downgrade)
Jan 20Amgen's (NASDAQ:AMGN) Upcoming Dividend Will Be Larger Than Last Year's
Jan 17Amgen: Strong Fundamentals But Expensive Valuation Justifies A Hold
Jan 05Amgen: MariTide Underwhelms, But There Are Ways To Win
Nov 26Amgen Sells Off: Keep Calm And Buy The Dip
Nov 18Amgen: A Biotech Giant Offering Value And Growth In A Frothy Market
Nov 03Amgen Q3 Earnings Review: So Many Questions, But MariTide Data Top Of The List
Oct 25CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | US$7b |
| Jun 30 2025 | n/a | n/a | US$7b |
| Mar 31 2025 | n/a | n/a | US$6b |
| Dec 31 2024 | US$24m | US$2m | US$4b |
| Sep 30 2024 | n/a | n/a | US$4b |
| Jun 30 2024 | n/a | n/a | US$3b |
| Mar 31 2024 | n/a | n/a | US$4b |
| Dec 31 2023 | US$23m | US$2m | US$7b |
| Sep 30 2023 | n/a | n/a | US$8b |
| Jun 30 2023 | n/a | n/a | US$8b |
| Mar 31 2023 | n/a | n/a | US$8b |
| Dec 31 2022 | US$21m | US$2m | US$7b |
| Sep 30 2022 | n/a | n/a | US$7b |
| Jun 30 2022 | n/a | n/a | US$7b |
| Mar 31 2022 | n/a | n/a | US$6b |
| Dec 31 2021 | US$22m | US$2m | US$6b |
| Sep 30 2021 | n/a | n/a | US$6b |
| Jun 30 2021 | n/a | n/a | US$6b |
| Mar 31 2021 | n/a | n/a | US$7b |
| Dec 31 2020 | US$20m | US$2m | US$7b |
| Sep 30 2020 | n/a | n/a | US$7b |
| Jun 30 2020 | n/a | n/a | US$7b |
| Mar 31 2020 | n/a | n/a | US$8b |
| Dec 31 2019 | US$20m | US$2m | US$8b |
| Sep 30 2019 | n/a | n/a | US$8b |
| Jun 30 2019 | n/a | n/a | US$8b |
| Mar 31 2019 | n/a | n/a | US$8b |
| Dec 31 2018 | US$19m | US$2m | US$8b |
Compensation vs Market: Bob's total compensation ($USD24.43M) is above average for companies of similar size in the US market ($USD13.44M).
Compensation vs Earnings: Bob's compensation has been consistent with company performance over the past year.
CEO
Bob Bradway (62 yo)
Mr. Robert A. Bradway, also known as Bob, has been the Chief Executive Officer of Amgen Inc. since May 23, 2012 and has been its President since May 2010. Mr. Bradway is responsible for the Amgen's global...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 15.6yrs | US$24.43m | 0.10% $ 184.1m | |
| Executive VP & CFO | 5.9yrs | US$7.81m | 0.0057% $ 10.3m | |
| Executive VP & CTO | 2yrs | US$8.13m | 0.0044% $ 8.0m | |
| Executive Vice President of Global Commercial Operations | 7.3yrs | US$8.47m | 0.0055% $ 9.8m | |
| Executive Vice President of Research & Development | 1yr | US$14.91m | no data | |
| Executive Vice President of Operations | 9.4yrs | US$7.21m | 0.013% $ 22.4m | |
| Chief Accounting Officer & VP of Finance | 2.3yrs | no data | 0.00058% $ 1.0m | |
| Senior VP & Chief Information Officer | 1.1yrs | no data | no data | |
| Senior VP of Global Research & Chief Scientific Officer | 1yr | no data | no data | |
| Executive Director of Investor Relations | no data | no data | no data | |
| Executive VP | 10.4yrs | US$7.24m | 0.0044% $ 7.9m | |
| Senior VP of Worldwide Compliance & Business Ethics and Chief Compliance Officer | 5.9yrs | no data | 0.0010% $ 1.9m |
Experienced Management: AMGN's management team is seasoned and experienced (5.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 14.2yrs | US$24.43m | 0.10% $ 184.1m | |
| Lead Independent Director | 13yrs | US$450.07k | 0.0013% $ 2.3m | |
| Co-Chair of Scientific Advisory Board | no data | US$292.01k | no data | |
| Co-Chair of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.4yrs | US$360.05k | 0.000080% $ 143.4k | |
| Independent Director | 8.8yrs | US$390.05k | 0.00023% $ 412.3k | |
| Independent Director | 12.2yrs | US$400.05k | 0.0024% $ 4.4m | |
| Independent Director | 9.2yrs | US$381.73k | 0.000080% $ 143.4k | |
| Independent Director | 7.6yrs | US$372.44k | 0.00040% $ 717.1k | |
| Independent Director | 13.6yrs | US$360.06k | 0.00064% $ 1.1m | |
| Independent Director | 8yrs | US$370.18k | 0.0014% $ 2.5m | |
| Member of Scientific Advisory Board of Cardiovascular & Metabolic | 1.9yrs | US$59.67k | 0.0012% $ 2.1m |
Experienced Board: AMGN's board of directors are considered experienced (9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/28 01:36 |
| End of Day Share Price | 2025/12/26 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Amgen Inc. is covered by 61 analysts. 30 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Brian Skorney | Baird |
| Aaron Gal | Bernstein |